Compare BSL & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSL | ALXO |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 172.8M |
| IPO Year | 2010 | 2020 |
| Metric | BSL | ALXO |
|---|---|---|
| Price | $12.96 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 47.6K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | ★ 9.55% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.45 | $0.86 |
| 52 Week High | $13.99 | $2.66 |
| Indicator | BSL | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 40.49 |
| Support Level | $12.87 | $1.03 |
| Resistance Level | $13.03 | $1.34 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 90.38 | 5.13 |
Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.